Spots Global Cancer Trial Database for dedifferentiated liposarcoma
Every month we try and update this database with for dedifferentiated liposarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | NCT03114527 | Soft Tissue Sar... | Ribociclib Everolimus | 18 Years - | Fox Chase Cancer Center | |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | NCT03307616 | Dedifferentiate... Recurrent Dedif... Recurrent Undif... Resectable Dedi... Resectable Undi... Undifferentiate... | Ipilimumab Nivolumab Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) | NCT06389799 | Dedifferentiate... | Pemigatinib Retifanlimab | 18 Years - 100 Years | Lund University Hospital | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | NCT00969917 | Dedifferentiate... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ph II Cabazitaxel DD Liposarcoma | NCT01913652 | Dedifferentiate... | Cabazitaxel | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma | NCT04979442 | Dedifferentiate... | RAIN-32 Trabectedin | 18 Years - | Rain Oncology Inc | |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery | NCT03307616 | Dedifferentiate... Recurrent Dedif... Recurrent Undif... Resectable Dedi... Resectable Undi... Undifferentiate... | Ipilimumab Nivolumab Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Abemaciclib in Dedifferentiated Liposarcoma | NCT02846987 | Sarcoma Dedifferentiate... | Abemaciclib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma | NCT05496569 | Dedifferentiate... | TQB3616 capsule TQB3616 placebo | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | NCT04242238 | Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate... | DCC-3014 Avelumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | NCT04242238 | Sarcoma Advanced Sarcom... High Grade Sarc... Leiomyosarcoma Undifferentiate... Myxofibrosarcom... Dedifferentiate... | DCC-3014 Avelumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
